Skp2: a novel potential therapeutic target for prostate cancer

Biochim Biophys Acta. 2012 Jan;1825(1):11-7. doi: 10.1016/j.bbcan.2011.09.002. Epub 2011 Sep 22.


Prostate cancer is the most frequently diagnosed tumor in men and the second most common cause of cancer-related death for males in the United States. It has been shown that multiple signaling pathways are involved in the pathogenesis of prostate cancer, such as androgen receptor (AR), Akt, Wnt, Hedgehog (Hh) and Notch. Recently, burgeoning amounts of evidence have implicated that the F-box protein Skp2 (S-phase kinase associated protein 2), a well-characterized oncoprotein, also plays a critical role in the development and progression of prostate cancer. Therefore, this review discusses the recent literature regarding the function and regulation of Skp2 in the pathogenesis of prostate cancer. Furthermore, we highlight that Skp2 may represent an attractive therapeutic target, thus warrants further development of agents to target Skp2, which could have significant therapeutic impact on prostate cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Disease Progression
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Molecular Targeted Therapy
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / therapy*
  • S-Phase Kinase-Associated Proteins / antagonists & inhibitors*
  • S-Phase Kinase-Associated Proteins / genetics
  • S-Phase Kinase-Associated Proteins / physiology
  • Signal Transduction


  • S-Phase Kinase-Associated Proteins